Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Aichi, Japan.
The Japan Rheumatism Friendship Association, Tokyo, Japan.
Mod Rheumatol. 2022 Feb 28;32(2):307-312. doi: 10.1080/14397595.2021.1913276.
This study aimed to evaluate patients' opinions regarding their rheumatoid arthritis (RA) therapy and to reflect the patients' perspectives in the 2020 update of the Japan College of Rheumatology clinical practice guidelines.
A self-administered questionnaire was mailed to 1600 members of the Japan Rheumatology Friendship Association, who were randomly selected by age and prefecture.
A total of 1156 patients returned the questionnaire (response rate, 72.3%; mean age, 63.0 ± 11.9 years). Those who reported having discussed their treatment goals with their doctors (450 respondents, 38.9%) were more likely to be satisfied with their current medical care (odds ratio, 7.13; 95% CI 4.72-10.8) compared with those who had not discussed their goals nor had them explained (287 respondents, 24.8%). The benefits exceeded the adverse effects for all pharmacotherapy (methotrexate, corticosteroids, conventional synthetic antirheumatic drugs, biological agents, Janus kinase inhibitor, and anti-RANKL antibodies). However, while 74.2% of the respondents using biological agents perceived that 'the favorable aspects outweighed the unfavorable aspects,' most of those taking anti-RANKL antibodies (69.2%) felt uncertain.
The questionnaire successfully collected information regarding patients' perceptions regarding their therapy. Further implementation of treat-to-target is necessary in Japan to improve patient satisfaction.
本研究旨在评估患者对类风湿关节炎（RA）治疗的看法，并反映患者对 2020 年版日本风湿病学会临床实践指南更新的观点。
通过邮寄的方式向日本风湿病之友协会的 1600 名成员发放了一份自填式问卷，这些成员是通过年龄和地区随机选择的。
共有 1156 名患者回复了问卷（应答率为 72.3%；平均年龄为 63.0±11.9 岁）。与那些未与医生讨论过治疗目标、也未被告知目标的患者（287 名，24.8%）相比，报告与医生讨论过治疗目标的患者（450 名，38.9%）对当前的医疗护理更满意（优势比，7.13；95%可信区间 4.72-10.8）。所有药物治疗（甲氨蝶呤、皮质类固醇、传统合成抗风湿药物、生物制剂、Janus 激酶抑制剂和抗 RANKL 抗体）的获益均超过不良反应。然而，虽然 74.2%使用生物制剂的患者认为“有利方面超过不利方面”，但大多数使用抗 RANKL 抗体的患者（69.2%）感到不确定。
该问卷成功收集了患者对治疗看法的信息。日本需要进一步实施达标治疗，以提高患者满意度。
